Literature DB >> 10321808

Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle.

H Yamashita1, Y Otsuki, K Matsumoto, K Ueki, M Ueki.   

Abstract

In this study, we investigate Fas ligand expression in the human endometrium during the menstrual cycle in relation to Fas antigen and Bcl-2 expression, using immunoelectron microscopy and Western blotting. Endometrial samples were obtained from 54 pre-menopausal non-pregnant women who underwent laparotomies for benign diseases. The Fas ligand, as well as the Fas antigen, were expressed on the surface of endometrial glandular cells throughout the menstrual cycle, whereas Bcl-2 showed a cyclic expression pattern, peaking during the late proliferative phase. A noteworthy finding was that both the Fas ligand and the Fas antigen were localized on Golgi apparatuses and vesicles, in addition to the cell membranes, during the late proliferative phase. These results indicate that the Fas ligand and Fas antigen which are localized on Golgi apparatus and vesicles during the late proliferative phase are incorporated into the cell membranes during the secretory phase, and are co-expressed on the cell membranes of endometrial glands throughout the menstrual cycle. The factors regulating Fas-mediated apoptosis in the human endometrium, including the level of expression of the Fas ligand and Bcl-2 are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321808     DOI: 10.1093/molehr/5.4.358

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  4 in total

1.  Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism.

Authors:  Dalya Rosner; Victoria Stoneman; Trevor Littlewood; Nicola McCarthy; Nichola Figg; Yinong Wang; George Tellides; Martin Bennett
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.

Authors:  Gabriela F Meresman; Carla Olivares; Susana Vighi; Margarita Alfie; Marcela Irigoyen; Juan J Etchepareborda
Journal:  Reprod Biol Endocrinol       Date:  2010-10-22       Impact factor: 5.211

3.  Development of endometrial cancer after long-term usage of the levonorgestrel-releasing intrauterine system.

Authors:  Alexander Steshenko; Leila Hanna; Damian Collins
Journal:  BMJ Case Rep       Date:  2021-05-13

4.  Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Authors:  Maria Quanz; Urs B Hagemann; Sabine Zitzmann-Kolbe; Beatrix Stelte-Ludwig; Sven Golfier; Cem Elbi; Dominik Mumberg; Karl Ziegelbauer; Christoph A Schatz
Journal:  Oncotarget       Date:  2018-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.